Recombinant hf-SCIg in inflammatory myositis: refining patient selection and outcome assessment. Author’s reply

We thank Tan [1] for his constructive comments on our multicentre real-world study evaluating recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin (hf-SCIg) in idiopathic inflammatory myositis (IIM) [2]. We appreciate the opportunity to further clarify some aspects of our work.